• 8978 Citations
  • 38 h-Index
1987 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Professor Howard Gurney is the Director of Clinical Trials for the Faculty of Medicine and Health Sciences at Macquarie University. 

Professor Gurney has a firm background in clinical research and has subspecialty interests in urogenital cancers including prostate, bladder, testis and kidney cancer. 

He has been the principal investigator for over 100 clinical trials and has published over 100 peer-reviewed articles in journals and book chapters.  Current research interests include the pharmacogenomics and therapeutic monitoring of chemotherapy and targeted therapies and he has published widely in this area.  He is regarded as a leading authority on mechanisms for safe dosing of anticancer agents and has held research grants and has written a number of invited editorials on these topics. 

Fingerprint Dive into the research topics where Howard Gurney is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 7 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

Research Outputs

A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer

Sternberg, C. N., Saad, F., Graff, J. N., Peer, A., Vaishampayan, U. N., Leung, E., Rosenbaum, E., Gurney, H., Epstein, R. J., Davis, I. D., Wu, B., Trandafir, L., Wagner, V. J. & Hussain, M., 1 Feb 2020, In : Annals of Oncology. 31, 2, p. 257-265 9 p.

Research output: Contribution to journalArticle

Open Access
File
  • 1 Citation (Scopus)

    Evaluating bioanalytical capabilities of paper spray ionization for abiraterone drug quantification in patient plasma

    Bhatnagar, A., McKay, M. J., Arasaratnam, M., Crumbaker, M., Gurney, H. & Molloy, M. P., 31 May 2020, (Accepted/In press) In : Journal of Mass Spectrometry.

    Research output: Contribution to journalArticle

  • Melphalan exposure and outcome in obese and non-obese adults with myeloma. A study of pharmacokinetics and pharmacodynamics

    Nath, C. E., Trotman, J., Nivison-Smith, I., Gurney, H., Zeng, L., Presgrave, P., Tiley, C., Joshua, D., Kerridge, I., McLachlan, A. J. & Shaw, P. J., 21 Feb 2020, In : Bone Marrow Transplantation. 3 p.

    Research output: Contribution to journalLetter

    The adverse effects of androgen deprivation therapy in prostate cancer and the benefits and potential anti-oncogenic mechanisms of progressive resistance training

    Lam, T., Birzniece, V., McLean, M., Gurney, H., Hayden, A. & Cheema, B. S., 13 Feb 2020, In : Sports Medicine - Open. 6, 1, p. 1-14 14 p., 13.

    Research output: Contribution to journalReview article

    Open Access
    File
  • The AGITG GAP Study: a Phase II study of perioperative gemcitabine and nab-paclitaxel for resectable pancreas cancer

    Barbour, A. P., Samra, J. S., Haghighi, K. S., Donoghoe, M. W., Burge, M., Harris, M. T., Chua, Y. J., Mitchell, J., O’Rourke, N., Chan, H., Gebski, V. J., Gananadha, S., Croagh, D. G., Kench, J. G., Goldstein, D. & Australasian Gastro-Intestinal Trials Group (AGITG) GAP investigators, 1 Jul 2020, In : Annals of Surgical Oncology. 27, 7, p. 2506-2515 10 p.

    Research output: Contribution to journalArticle